Benzinga · Oct 9, 2026
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $118 to $140.
HA
NASDAQ · HAE
Haemonetics Corporation
Healthcare · Medical - Instruments & Supplies
$121.72
Down-$0.61 (-0.50%)
Updated Oct 15, 2026, 1:15 AM
SID Score
6.9/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.12B
- P/E ratio
- 23.87
- Dividend yield
- 0.00%
- 52-week range
- $48.17 – $122.24
- Volume
- 829.19K
- Avg. volume
- 976.76K
Price performance · HAE
HAE price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
HAE closed at $121.72 after 20 trading sessions, up 14.57% for the selected period.
- Last close
- $121.72
- Period change
- +14.57%
- Period low
- $101.71
- Period high
- $122.06
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $122.80 | $123.77 | $121.045 | $121.72 | 829.19K |
| Oct 12, 2026 | $118.70 | $122.24 | $118.355 | $122.06 | 895.09K |
| Oct 9, 2026 | $119.81 | $121.1925 | $116.515 | $118.69 | 1.25M |
| Oct 8, 2026 | $115.00 | $121.00 | $111.66 | $119.47 | 2.78M |
| Oct 7, 2026 | $103.48 | $104.02 | $101.315 | $101.71 | 625.58K |
| Oct 6, 2026 | $104.92 | $105.58 | $102.80 | $103.52 | 542.05K |
| Oct 5, 2026 | $104.29 | $106.26 | $103.645 | $104.68 | 652.65K |
| Oct 2, 2026 | $104.58 | $105.70 | $103.61 | $104.68 | 328.57K |
| Oct 1, 2026 | $105.71 | $106.67 | $103.51 | $104.37 | 454.25K |
| Sep 30, 2026 | $105.42 | $105.78 | $103.54 | $105.30 | 508.9K |
| Sep 29, 2026 | $104.99 | $106.52 | $104.60 | $105.80 | 451.22K |
| Sep 28, 2026 | $105.14 | $106.215 | $104.435 | $105.79 | 472.15K |
| Sep 25, 2026 | $105.72 | $106.58 | $104.71 | $105.30 | 492.6K |
| Sep 24, 2026 | $106.67 | $108.22 | $105.92 | $106.00 | 416.8K |
| Sep 23, 2026 | $108.56 | $110.28 | $106.70 | $106.82 | 704.88K |
| Sep 22, 2026 | $109.26 | $110.14 | $108.38 | $108.52 | 446.6K |
| Sep 21, 2026 | $109.24 | $110.055 | $108.05 | $108.73 | 327.03K |
| Sep 18, 2026 | $108.95 | $110.45 | $107.60 | $108.40 | 1.3M |
| Sep 17, 2026 | $108.39 | $109.83 | $107.56 | $107.60 | 621.12K |
| Sep 16, 2026 | $105.90 | $106.78 | $104.78 | $106.24 | 520.72K |
Latest HAE news
The latest Smart Investors Daily articles mentioning HAE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
HAE research
Overview
Company profile and research snapshot.
Company profile
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $82.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 9, 2026 | Mizuho | Outperform | — |
| Oct 9, 2026 | Barrington Research | Outperform | — |
| Oct 8, 2026 | BTIG | Buy | — |
| Sep 17, 2026 | Citigroup | Buy | — |
| Sep 3, 2026 | Raymond James | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 9, 2026
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $140.
SeekingAlpha · Oct 9, 2026
Haemonetics: CSL Plasma Improves The Outlook, Not The Entry Point (Rating Downgrade)
Yahoo · Oct 9, 2026
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
